Form 8-K - Current report:
SEC Accession No. 0001785530-24-000033
Filing Date
2024-11-07
Accepted
2024-11-07 09:06:55
Documents
16
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K howl-20241107.htm   iXBRL 8-K 33360
2 EX-99.1 a09302024ex991.htm EX-99.1 78824
3 EX-99.2 a09302024ex992.htm EX-99.2 20497
7 werewolflogohorizontala.jpg GRAPHIC 277881
  Complete submission text file 0001785530-24-000033.txt   663748

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT howl-20241107.xsd EX-101.SCH 1829
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT howl-20241107_lab.xml EX-101.LAB 23449
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT howl-20241107_pre.xml EX-101.PRE 13623
18 EXTRACTED XBRL INSTANCE DOCUMENT howl-20241107_htm.xml XML 3016
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40366 | Film No.: 241433457
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)